MCID: ADR004
MIFTS: 48

Adrenal Cortical Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adrenal Cortical Adenocarcinoma

MalaCards integrated aliases for Adrenal Cortical Adenocarcinoma:

Name: Adrenal Cortical Adenocarcinoma 12 15
Adrenal Cortex Adenocarcinoma 12
Adrenocortical Carcinoma 74

Classifications:



External Ids:

Disease Ontology 12 DOID:3959
UMLS 74 C0206686

Summaries for Adrenal Cortical Adenocarcinoma

Disease Ontology : 12 An adrenocortical carcinoma that originates in the cortex of the adrenal gland and derives from epithelial cells of glandular origin.

MalaCards based summary : Adrenal Cortical Adenocarcinoma, also known as adrenal cortex adenocarcinoma, is related to legius syndrome and breast adenocarcinoma, and has symptoms including fever and flank pain. An important gene associated with Adrenal Cortical Adenocarcinoma is BAD (BCL2 Associated Agonist Of Cell Death), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal gland and adrenal cortex, and related phenotypes are Decreased cell migration and Decreased viability with paclitaxel

Related Diseases for Adrenal Cortical Adenocarcinoma

Diseases related to Adrenal Cortical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 legius syndrome 9.9 SPRY1 SPRY2
2 breast adenocarcinoma 9.6 EGF PTEN SH3KBP1
3 endometrial cancer 9.4 EGF MAPK3 MME PTEN

Symptoms & Phenotypes for Adrenal Cortical Adenocarcinoma

UMLS symptoms related to Adrenal Cortical Adenocarcinoma:


fever, flank pain

GenomeRNAi Phenotypes related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.26 CBL MAPK3 RPS6KA1 SPRY1
2 Decreased viability with paclitaxel GR00179-A-1 9.23 MAPK3 SP1
3 Decreased viability with paclitaxel GR00179-A-3 9.23 MAPK3 SP1

MGI Mouse Phenotypes related to Adrenal Cortical Adenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.8 BAD CBL EGF MAPK3 PTEN SPRY1
2 integument MP:0010771 9.7 CBL EGF MAPK3 MME PTEN SH3KBP1
3 liver/biliary system MP:0005370 9.43 CBL DECR1 MAPK3 MME PTEN SP1
4 neoplasm MP:0002006 9.02 BAD MAPK3 PTEN SPRY1 SPRY2

Drugs & Therapeutics for Adrenal Cortical Adenocarcinoma

Drugs for Adrenal Cortical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
2
Racepinephrine Approved Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
3
Mecasermin Approved, Investigational Phase 3 68562-41-4
4
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
5
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
6
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
7
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
8
Mitotane Approved Phase 3,Phase 2 53-19-0 4211
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
12
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
13
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2 50-03-3
14
Etomidate Approved Phase 3,Phase 1,Phase 2 33125-97-2 667484 36339
15
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
16
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
18 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
19 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
20 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
21 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
22 Cola Phase 3,Phase 2,Phase 1,Early Phase 1
23 Epinephryl borate Phase 3,Phase 2,Phase 1,Not Applicable
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Bronchodilator Agents Phase 3,Phase 2,Not Applicable
26 Adrenergic alpha-Agonists Phase 3,Phase 2,Not Applicable
27 Adrenergic Agonists Phase 3,Phase 2,Not Applicable
28 Adrenergic beta-Agonists Phase 3,Phase 2,Not Applicable
29 Sympathomimetics Phase 3,Phase 2,Not Applicable
30 Respiratory System Agents Phase 3,Phase 2,Not Applicable
31 Vasoconstrictor Agents Phase 3,Phase 2,Not Applicable
32 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
33 Autonomic Agents Phase 3,Phase 2,Not Applicable
34 Mydriatics Phase 3,Phase 2,Not Applicable
35 Anti-Asthmatic Agents Phase 3,Phase 2,Not Applicable
36 Adrenergic Agents Phase 3,Phase 2,Not Applicable
37 insulin Phase 3,Phase 2
38 Insulin, Globin Zinc Phase 3,Phase 2
39 Mitogens Phase 3,Phase 2
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2
41 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
42 Etoposide phosphate Phase 3,Phase 2
43 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
44 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
45 Immunologic Factors Phase 3,Phase 2,Phase 1
46 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
47 Narcotics Phase 3
48 Adjuvants, Anesthesia Phase 3
49 Analgesics Phase 3
50 Anesthetics, Intravenous Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
2 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
3 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
6 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
7 Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
8 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
9 Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Recruiting NCT00777244 Phase 3 MITOTANE
10 Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia Recruiting NCT02010957 Phase 3
11 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
12 Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
13 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
14 Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
15 Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
16 Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
17 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
18 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
19 Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
20 Sunitinib in Refractory Adrenocortical Carcinoma Completed NCT00453895 Phase 2 Sunitinib
21 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
22 Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
23 A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients Completed NCT01262235 Phase 1, Phase 2 TKM-080301
24 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
25 A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent Completed NCT00264433 Phase 2 ADH -1 (Exherin™)
26 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Completed NCT02468193 Phase 2 Osilodrostat
27 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
28 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
29 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
30 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Completed NCT02804750 Phase 2 CORT125134
31 Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
32 Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
33 Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
34 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
35 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
36 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
37 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
38 Extension Study to Evaluate the Safety and Clinical Benefit of Long-Term Use of Relacorilant in Patients With Cushing Syndrome Recruiting NCT03604198 Phase 2 relacorilant
39 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
40 Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting NCT02673333 Phase 2 Pembrolizumab
41 Cabozantinib in Advanced Adrenocortical Carcinoma Not yet recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
42 S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
43 Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Terminated NCT02720484 Phase 2 Nivolumab
44 IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Terminated NCT00778817 Phase 2 mitotane
45 Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
46 Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Withdrawn NCT00469469 Phase 2 Bevacizumab
47 Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
48 Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
49 A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome Completed NCT01981525 Phase 1 Metformin
50 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide

Search NIH Clinical Center for Adrenal Cortical Adenocarcinoma

Genetic Tests for Adrenal Cortical Adenocarcinoma

Anatomical Context for Adrenal Cortical Adenocarcinoma

MalaCards organs/tissues related to Adrenal Cortical Adenocarcinoma:

42
Cortex, Adrenal Gland, Adrenal Cortex, Liver, Bone, Lung, Testes

Publications for Adrenal Cortical Adenocarcinoma

Articles related to Adrenal Cortical Adenocarcinoma:

(show top 50) (show all 1193)
# Title Authors Year
1
Precocious pseudopuberty due to virilising adrenocortical carcinoma progressing to central precocious puberty after surgery. ( 30862670 )
2019
2
Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases. ( 30936196 )
2019
3
Establishing a human adrenocortical carcinoma (ACC)-specific gene mutation signature. ( 30477734 )
2019
4
Clinical and molecular prognostic factors in adrenocortical carcinoma. ( 30221891 )
2019
5
18F-FDG PET reveals an adrenocortical carcinoma in a bilateral adrenal multinodular disease. ( 30251165 )
2019
6
Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. ( 30315857 )
2019
7
In vitro antitumor activity of progesterone in human adrenocortical carcinoma. ( 30367443 )
2019
8
Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. ( 30443830 )
2019
9
Advanced Adrenocortical Carcinoma - What to do when First-Line Therapy Fails? ( 30469158 )
2019
10
Fascin-1 Is a Novel Prognostic Biomarker Associated With Tumor Invasiveness in Adrenocortical Carcinoma. ( 30476173 )
2019
11
Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. ( 30481155 )
2019
12
Case Report of an Adrenocortical Carcinoma Associated With Germline CHEK2 Mutation. ( 30623166 )
2019
13
Adrenocortical carcinoma in patients with MEN1: a kindred report and review of the literature. ( 30721134 )
2019
14
Operative Management of Recurrent and Metastatic Adrenocortical Carcinoma: A Systematic Review. ( 30760340 )
2019
15
Targeted assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma. ( 30770352 )
2019
16
Management of Adrenocortical Carcinoma. ( 30798468 )
2019
17
Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma. ( 30816525 )
2019
18
A case of metastatic adrenocortical carcinoma. ( 30863550 )
2019
19
Identification of four hub genes associated with adrenocortical carcinoma progression by WGCNA. ( 30886771 )
2019
20
Adjuvant radiotherapy after surgical resection for adrenocortical carcinoma: A systematic review of observational studies and meta-analysis. ( 30900615 )
2019
21
Label-free impedimetric immunosensor based on arginine-functionalized gold nanoparticles for detection of DHEAS, a biomarker of pediatric adrenocortical carcinoma. ( 30909017 )
2019
22
microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma. ( 30918109 )
2019
23
Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management. ( 30942448 )
2019
24
Adrenocortical carcinoma associated with giant bilateral myelolipomas in classic congenital adrenal hyperplasia. ( 30945697 )
2019
25
Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. ( 30970324 )
2019
26
Apoptosis regulation in adrenocortical carcinoma. ( 30978697 )
2019
27
Adrenocortical carcinoma: presentation and outcome of a contemporary patient series. ( 30980285 )
2019
28
SIRT6 abrogation promotes adrenocortical carcinoma through activation of NF-κB signaling. ( 30989475 )
2019
29
Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. ( 30991359 )
2019
30
Massive Migration of an Adrenocortical Carcinoma Thrombus. ( 31030537 )
2019
31
Diagnostic Role of Prostate-Specific Membrane Antigen in Adrenocortical Carcinoma. ( 31040822 )
2019
32
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. ( 31057613 )
2019
33
A clinical study and treatment results of adrenocortical carcinoma patients presented in Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore. ( 31105294 )
2019
34
Co-culture of H295R Adrenocortical Carcinoma and BeWo Choriocarcinoma Cells to Study Feto-placental Interactions: Focus on Estrogen Biosynthesis. ( 29197012 )
2018
35
Adrenocortical Carcinoma Presenting as Reversible Dilated Cardiomyopathy. ( 30505399 )
2018
36
High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma. ( 29192018 )
2018
37
Incidentally detected adrenocortical carcinoma in familial adenomatous polyposis: an unusual presentation of a hereditary cancer syndrome. ( 30181409 )
2018
38
Adrenocortical carcinoma characterized by gynecomastia: A case report. ( 29403152 )
2018
39
The coexistence of Cushing syndrome and gynecomastia as the manifestations of adrenocortical carcinoma. ( 30527206 )
2018
40
Ectopic, retroperitoneal adrenocortical carcinoma in the setting of Lynch syndrome. ( 28940135 )
2018
41
Synchronous adrenocortical carcinoma and ovarian malignant mixed germ cell tumor: A case report and literature review. ( 29768344 )
2018
42
RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. ( 30558313 )
2018
43
Adrenocortical carcinoma (ACC): When and why should we consider germline testing? ( 30104051 )
2018
44
Predictors of Survival in Adrenocortical Carcinoma: An Analysis From the National Cancer Database. ( 29982685 )
2018
45
A Rare Adrenal Incidentaloma That Mimics Adrenocortical Carcinoma. ( 29984033 )
2018
46
European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. ( 30042120 )
2018
47
Feminizing Adrenocortical Carcinoma: The Source of Estrogen Production and the Role of Adrenal-Gonadal Dedifferentiation. ( 30053001 )
2018
48
Pathobiology and genetics of adrenocortical carcinoma. ( 30072419 )
2018
49
Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients. ( 30087117 )
2018
50
Adrenocortical carcinoma misdiagnosed as hepatocellular carcinoma. ( 30102237 )
2018

Variations for Adrenal Cortical Adenocarcinoma

Expression for Adrenal Cortical Adenocarcinoma

Search GEO for disease gene expression data for Adrenal Cortical Adenocarcinoma.

Pathways for Adrenal Cortical Adenocarcinoma

Pathways related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 BAD CBL EGF MAPK3 PTEN RPS6KA1
2
Show member pathways
13.9 BAD CBL EGF MAPK3 MME PTEN
3
Show member pathways
13.32 BAD CBL EGF MAPK3 PTEN SH3KBP1
4
Show member pathways
13.15 BAD CBL EGF MAPK3 RPS6KA1
5
Show member pathways
13.1 BAD CBL EGF MAPK3 PTEN RPS6KA1
6
Show member pathways
12.81 BAD CBL EGF MAPK3 PTEN RPS6KA1
7
Show member pathways
12.79 BAD EGF MAPK3 PTEN
8
Show member pathways
12.76 BAD CBL EGF MAPK3 PTEN
9
Show member pathways
12.75 BAD MAPK3 PTEN RPS6KA1
10 12.74 BAD CBL EGF MAPK3 PTEN SP1
11
Show member pathways
12.68 BAD CBL MAPK3 PTEN RPS6KA1
12
Show member pathways
12.66 BAD EGF MAPK3 PTEN SP1
13
Show member pathways
12.61 BAD CBL EGF MAPK3 PTEN SH3KBP1
14
Show member pathways
12.58 BAD EGF MAPK3 SP1
15
Show member pathways
12.58 BAD CBL MAPK3 PTEN RPS6KA1 SH3KBP1
16
Show member pathways
12.56 CBL MAPK3 PTEN SP1
17
Show member pathways
12.5 BAD CBL EGF MAPK3 SP1
18
Show member pathways
12.49 BAD CBL EGF MAPK3 RPS6KA1
19
Show member pathways
12.48 BAD CBL MAPK3 PTEN
20
Show member pathways
12.42 CBL MAPK3 PTEN RPS6KA1
21
Show member pathways
12.35 BAD CBL MAPK3 RPS6KA1
22
Show member pathways
12.31 BAD CBL MAPK3 PTEN RPS6KA1
23
Show member pathways
12.3 CBL MAPK3 PTEN RPS6KA1
24
Show member pathways
12.3 BAD CBL MAPK3 PTEN RPS6KA1 SP1
25
Show member pathways
12.3 BAD CBL EGF MAPK3 PTEN SP1
26
Show member pathways
12.24 BAD CBL MAPK3 RPS6KA1 SP1
27
Show member pathways
12.22 EGF MAPK3 RPS6KA1
28
Show member pathways
12.22 CBL MAPK3 PTEN
29
Show member pathways
12.17 CBL MAPK3 SPRY2
30
Show member pathways
12.12 MAPK3 RPS6KA1 SP1
31
Show member pathways
12.09 BAD MAPK3 RPS6KA1
32
Show member pathways
12.06 CBL EGF MAPK3 PTEN
33
Show member pathways
12.06 BAD CBL MAPK3 PTEN RPS6KA1
34 12.05 BAD PTEN SP1
35 12.02 BAD MAPK3 RPS6KA1
36
Show member pathways
11.99 EGF MAPK3 PTEN
37
Show member pathways
11.97 CBL MAPK3 RPS6KA1
38 11.97 CBL EGF SH3KBP1 SPRY1 SPRY2
39
Show member pathways
11.95 BAD MAPK3 RPS6KA1
40 11.95 BAD MAPK3 PTEN
41
Show member pathways
11.93 BAD MAPK3 RPS6KA1
42 11.87 EGF MAPK3 PTEN
43 11.83 BAD EGF MAPK3
44 11.71 BAD MAPK3 RPS6KA1 SPRY1 SPRY2
45 11.62 EGF MAPK3 SP1
46
Show member pathways
11.52 CBL EGF MAPK3
47 11.41 BAD EGF MAPK3
48 11.41 CBL MAPK3 RPS6KA1 SPRY2
49 11.38 CBL EGF PTEN RPS6KA1 SH3KBP1 SP1
50
Show member pathways
11.32 CBL EGF SH3KBP1 SPRY1 SPRY2

GO Terms for Adrenal Cortical Adenocarcinoma

Cellular components related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.81 BAD CBL DECR1 MAPK3 PTEN RPS6KA1
2 cytoplasm GO:0005737 9.65 BAD CBL MAPK3 MME PTEN RPS6KA1
3 focal adhesion GO:0005925 8.92 CBL MAPK3 MME SH3KBP1

Biological processes related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.86 CBL PTEN RPS6KA1 SPRY2
2 apoptotic process GO:0006915 9.77 BAD MAPK3 PTEN RPS6KA1 SH3KBP1
3 membrane organization GO:0061024 9.63 CBL EGF SH3KBP1
4 response to ethanol GO:0045471 9.58 BAD CBL PTEN
5 response to testosterone GO:0033574 9.57 BAD CBL
6 ERK1 and ERK2 cascade GO:0070371 9.55 EGF MAPK3
7 branching morphogenesis of an epithelial tube GO:0048754 9.54 EGF SPRY2
8 negative regulation of Ras protein signal transduction GO:0046580 9.52 SPRY1 SPRY2
9 establishment of mitotic spindle orientation GO:0000132 9.51 SPRY1 SPRY2
10 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.5 PTEN SPRY1 SPRY2
11 lung morphogenesis GO:0060425 9.49 MAPK3 SPRY2
12 negative regulation of fibroblast growth factor receptor signaling pathway GO:0040037 9.48 SPRY1 SPRY2
13 positive regulation of ubiquitin-dependent protein catabolic process GO:2000060 9.43 EGF PTEN
14 positive regulation of gene expression GO:0010628 9.35 EGF MAPK3 PTEN SP1 SPRY2
15 bud elongation involved in lung branching GO:0060449 9.26 SPRY1 SPRY2
16 negative regulation of neurotrophin TRK receptor signaling pathway GO:0051387 9.16 SPRY1 SPRY2
17 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 9.02 CBL EGF SH3KBP1 SPRY1 SPRY2

Molecular functions related to Adrenal Cortical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.26 BAD CBL PTEN SPRY2
2 epidermal growth factor receptor binding GO:0005154 9.16 CBL EGF
3 protein tyrosine kinase binding GO:1990782 8.62 CBL PTEN

Sources for Adrenal Cortical Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....